Chemotherapy before surgery for advanced pancreatic cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests giving chemotherapy before any surgery to people with borderline resectable or locally advanced pancreatic cancer. The goal is to shrink the tumor, which may make surgery more successful and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with pancreatic cancer (adenocarcinoma), or a mixed tumor where adenocarcinoma is the main type.
- Your cancer is considered borderline resectable or locally advanced, meaning it is not easily removable by surgery at this time.
- You are 18 years or older.
- You are generally well enough to be up and about (ECOG score 0-1).
- Your blood counts and organ function (liver and kidneys) are within acceptable ranges.
- You have not had prior chemotherapy with gemcitabine, nab-paclitaxel, or FOLFIRINOX for pancreatic cancer.
- You have no other cancer in the last 3 years, except for certain non-melanoma skin cancers or treated low-risk prostate cancer.
- You are not pregnant or breastfeeding.
- You are willing to sign a consent form and follow the study plan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether giving chemotherapy before surgery, and possibly adding a focused high-dose radiation treatment, can improve outcomes for people with borderline resectable pancreatic cancer. It aims to shrink or control the cancer and help more patients get to surgery safely.
This trial tests whether giving two already-approved chemotherapy drugs and radiation before surgery works better for localized pancreatic cancer. It’s meant for people whose cancer looks removable by surgery and who haven’t had prior pancreatic cancer treatment.
This trial tests whether taking chemotherapy for a longer period before surgery can help people with borderline or locally advanced pancreatic cancer. It aims to see if a longer treatment course leads to better outcomes.
This trial compares two approaches for patients with pancreatic or periampullary cancer that can be surgically removed: getting chemotherapy before surgery (neoadjuvant therapy) versus surgery first. It aims to find out which sequence leads to better outcomes.
This trial tests giving chemotherapy before surgery for people with borderline resectable pancreatic cancer, to try to make surgery more successful. It also checks whether the study treatment is safe and helps tumors before the operation.
This trial tests a three-drug chemotherapy combination (gemcitabine, cisplatin, and nab-paclitaxel) given before surgery for people with pancreatic cancer that can be removed or is on the edge of being removable. The goal is to shrink the tumor and improve surgery outcomes.
Hear when a new Borderline Resectable Pancreatic Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.